Symptomatic cryoglobulinemia.

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

1. Treatment of symptomatic cryoglobulinemia is exceedingly challenging due to the multisystemic nature of its presentation, the variability of its course, and the paucity of effective therapeutic options supported by randomized controlled clinical trials. 2. Patients with mild, relatively asymptomatic disease should be observed without introduction of systemic therapy. 3. Patients with symptomatic type I secondary cryoglobulinemia should be treated as appropriate for their underlying lymphoproliferative or plasmaproliferative disorder. 4. Patients with secondary type II or type III cryoglobulinemia should be treated for their underlying connective tissue, lymphoproliferative, or liver disorder or infection. 5. First line treatment for symptomatic, essential type II or type III cryoglobulinemia associated with hepatitis C should include interferon (IFN)-alpha. Depending on the severity of clinical presentation, adjuvant corticosteroids or plasmapheresis should be considered. 6. Life-threatening or acute organ-threatening presentations should be managed with combined modality therapy, which should include high-dose corticosteroid, plasmapheresis, or alkylator-based therapy. 7. Many chemotherapeutic and immunosuppressive strategies have been tried but not systematically tested; their value is therefore unknown. 8. Challenges for the future of treating symptomatic cryoglobulinemia include devising better therapies and more systematic evaluation of existing therapies.

Original languageEnglish (US)
Pages (from-to)105-118
Number of pages14
JournalCurrent Treatment Options in Oncology
Volume1
Issue number2
StatePublished - Jun 2000

Fingerprint

Cryoglobulinemia
Plasmapheresis
Therapeutics
Adrenal Cortex Hormones
Asymptomatic Diseases
Combined Modality Therapy
Alkylating Agents
Immunosuppressive Agents
Hepatitis C
Interferon-alpha
Connective Tissue
Randomized Controlled Trials
Liver
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Symptomatic cryoglobulinemia. / Dispenzieri, Angela.

In: Current Treatment Options in Oncology, Vol. 1, No. 2, 06.2000, p. 105-118.

Research output: Contribution to journalArticle

@article{6b53f2494f7844838cb3f0f753ef4b34,
title = "Symptomatic cryoglobulinemia.",
abstract = "1. Treatment of symptomatic cryoglobulinemia is exceedingly challenging due to the multisystemic nature of its presentation, the variability of its course, and the paucity of effective therapeutic options supported by randomized controlled clinical trials. 2. Patients with mild, relatively asymptomatic disease should be observed without introduction of systemic therapy. 3. Patients with symptomatic type I secondary cryoglobulinemia should be treated as appropriate for their underlying lymphoproliferative or plasmaproliferative disorder. 4. Patients with secondary type II or type III cryoglobulinemia should be treated for their underlying connective tissue, lymphoproliferative, or liver disorder or infection. 5. First line treatment for symptomatic, essential type II or type III cryoglobulinemia associated with hepatitis C should include interferon (IFN)-alpha. Depending on the severity of clinical presentation, adjuvant corticosteroids or plasmapheresis should be considered. 6. Life-threatening or acute organ-threatening presentations should be managed with combined modality therapy, which should include high-dose corticosteroid, plasmapheresis, or alkylator-based therapy. 7. Many chemotherapeutic and immunosuppressive strategies have been tried but not systematically tested; their value is therefore unknown. 8. Challenges for the future of treating symptomatic cryoglobulinemia include devising better therapies and more systematic evaluation of existing therapies.",
author = "Angela Dispenzieri",
year = "2000",
month = "6",
language = "English (US)",
volume = "1",
pages = "105--118",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Symptomatic cryoglobulinemia.

AU - Dispenzieri, Angela

PY - 2000/6

Y1 - 2000/6

N2 - 1. Treatment of symptomatic cryoglobulinemia is exceedingly challenging due to the multisystemic nature of its presentation, the variability of its course, and the paucity of effective therapeutic options supported by randomized controlled clinical trials. 2. Patients with mild, relatively asymptomatic disease should be observed without introduction of systemic therapy. 3. Patients with symptomatic type I secondary cryoglobulinemia should be treated as appropriate for their underlying lymphoproliferative or plasmaproliferative disorder. 4. Patients with secondary type II or type III cryoglobulinemia should be treated for their underlying connective tissue, lymphoproliferative, or liver disorder or infection. 5. First line treatment for symptomatic, essential type II or type III cryoglobulinemia associated with hepatitis C should include interferon (IFN)-alpha. Depending on the severity of clinical presentation, adjuvant corticosteroids or plasmapheresis should be considered. 6. Life-threatening or acute organ-threatening presentations should be managed with combined modality therapy, which should include high-dose corticosteroid, plasmapheresis, or alkylator-based therapy. 7. Many chemotherapeutic and immunosuppressive strategies have been tried but not systematically tested; their value is therefore unknown. 8. Challenges for the future of treating symptomatic cryoglobulinemia include devising better therapies and more systematic evaluation of existing therapies.

AB - 1. Treatment of symptomatic cryoglobulinemia is exceedingly challenging due to the multisystemic nature of its presentation, the variability of its course, and the paucity of effective therapeutic options supported by randomized controlled clinical trials. 2. Patients with mild, relatively asymptomatic disease should be observed without introduction of systemic therapy. 3. Patients with symptomatic type I secondary cryoglobulinemia should be treated as appropriate for their underlying lymphoproliferative or plasmaproliferative disorder. 4. Patients with secondary type II or type III cryoglobulinemia should be treated for their underlying connective tissue, lymphoproliferative, or liver disorder or infection. 5. First line treatment for symptomatic, essential type II or type III cryoglobulinemia associated with hepatitis C should include interferon (IFN)-alpha. Depending on the severity of clinical presentation, adjuvant corticosteroids or plasmapheresis should be considered. 6. Life-threatening or acute organ-threatening presentations should be managed with combined modality therapy, which should include high-dose corticosteroid, plasmapheresis, or alkylator-based therapy. 7. Many chemotherapeutic and immunosuppressive strategies have been tried but not systematically tested; their value is therefore unknown. 8. Challenges for the future of treating symptomatic cryoglobulinemia include devising better therapies and more systematic evaluation of existing therapies.

UR - http://www.scopus.com/inward/record.url?scp=0034211636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034211636&partnerID=8YFLogxK

M3 - Article

C2 - 12057048

AN - SCOPUS:0034211636

VL - 1

SP - 105

EP - 118

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

ER -